T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179 · see citing works

Cancer statistics, 2018

Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632 · see citing works

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030 · see citing works

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · see citing works

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works

Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis

Watanabe‐Fukunaga, R., Brannan, C., Copeland, N., Jenkins, N., & Nagata, S. (1992) · Nature · doi:10.1038/356314a0 · Cited by 3,153 · see citing works

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898 · see citing works

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688 · see citing works

FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis

Chinnaiyan, A. M., O'Rourke, K., Tewari, M., & Dixit, V. M. (1995) · Cell · doi:10.1016/0092-8674(95)90071-3 · Cited by 2,431 · see citing works

Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor.

Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., & Peter, M. E. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00245.x · Cited by 2,181 · see citing works

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,145 · see citing works

A human memory T cell subset with stem cell–like properties

Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · see citing works

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729 · see citing works

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C.-H., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,635 · see citing works

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Schuster, S., Svoboda, J., Chong, E., Nasta, S., Mato, A., Anak, Ö., Brogdon, J., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,599 · see citing works

Fas and Perforin Pathways as Major Mechanisms of T Cell-Mediated Cytotoxicity

Kägi, D., Vignaux, F., Ledermann, B., Bürki, K., Depraetere, V., Nagata, S., Hengartner, H., & Golstein, P. (1994) · Science · doi:10.1126/science.7518614 · Cited by 1,513 · see citing works

Phenotypic and functional separation of memory and effector human CD8+ T cells

Hamann, D., Baars, P. A., Rep, M. H. G., Hooibrink, B., Kerkhof-Garde, S. R., Klein, M. R., & Lier, R. A. W. V. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.9.1407 · Cited by 1,366 · see citing works

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science · doi:10.1126/science.aaf2807 · Cited by 1,348 · cited 1× · see citing works

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Fry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,336 · see citing works

FLICE is activated by association with the CD95 death‐inducing signaling complex (DISC)

Medema, J. P., Scaffidi, C., Kischkel, F. C., Shevchenko, A., Mann, M., Krammer, P. H., & Peter, M. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2794 · Cited by 1,189 · see citing works

Lpr and gld: Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease

Cohen, P. L., & Eisenberg, R. A. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001331 · Cited by 1,169 · see citing works

Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma

Louis, C. U., Savoldo, B., Dotti, G., Pulè, M. A., Yvon, E. S., Myers, G. D., Rössig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,162 · see citing works

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,075 · see citing works

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025 · see citing works

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor–modified T cells

Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · cited 1× · see citing works

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004 · see citing works

A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain

Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H., & Wallach, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.14.7795 · Cited by 993 · see citing works

Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors

Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R., Hagemann, I., Lal, P., Feldman, M., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 980 · see citing works

Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells

Klebanoff, C. A., Gattinoni, L., Torabi‐Parizi, P., Kerstann, K. W., Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A., Hwang, S. T., Rosenberg, S. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503726102 · Cited by 961 · see citing works

Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth‐Dreese, F. A., Dellemijn, T. A. M., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 927 · see citing works

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2015) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 864 · see citing works

An inducible caspase 9 safety switch for T-cell therapy

Straathof, K. C. M., Pulè, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-11-4564 · Cited by 745 · see citing works

Ionic immune suppression within the tumour microenvironment limits T cell effector function

Eil, R. L., Vodnala, S. K., Clever, D. C., Klebanoff, C. A., Sukumar, M., Pan, J. H., Palmer, D. C., Gros, A., Yamamoto, T. N., Patel, S. J., et al. (2016) · Nature · doi:10.1038/nature19364 · Cited by 680 · see citing works

Fas Preassociation Required for Apoptosis Signaling and Dominant Inhibition by Pathogenic Mutations

Siegel, R. M., Frederiksen, J. K., Zacharias, D. A., Chan, F. K.-M., Johnson, M. M., Lynch, D. H., Tsien, R. Y., & Lenardo, M. J. (2000) · Science · doi:10.1126/science.288.5475.2354 · Cited by 659 · see citing works

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 623 · see citing works

Comprehensive analysis of normal adjacent to tumor transcriptomes

Aran, D., Camarda, R., Odegaard, J. I., Paik, H., Oskotsky, B., Krings, G., Goga, A., Sirota, M., & Butte, A. J. (2017) · Nature Communications · doi:10.1038/s41467-017-01027-z · Cited by 619 · see citing works

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

Wang, X., Chang, W.-C., Wong, C. W., Colcher, D. M., Sherman, M. A., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600 · see citing works

Paths to stemness: building the ultimate antitumour T cell

Gattinoni, L., Klebanoff, C. A., & Restifo, N. P. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3322 · Cited by 599 · see citing works

Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells

Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P., & Shields, J. D. (2018) · Nature Communications · doi:10.1038/s41467-018-03347-0 · Cited by 578 · see citing works

Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels

Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S. L., Yang, J. C., Sherry, R. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3024 · Cited by 569 · see citing works

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

Heczey, A. A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A. G., Grilley, B., Liu, H., Wu, M. F., Mei, Z., Gee, A. P., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.012 · Cited by 535 · see citing works

PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

Chong, E. A., Melenhorst, J. J., Lacey, S. F., Ambrose, D. E., Gonzalez, V. E., Levine, B. L., June, C. H., & Schuster, S. J. (2016) · Blood · doi:10.1182/blood-2016-09-738245 · Cited by 498 · see citing works

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma

D’Angelo, S. P., Melchiori, L., Merchant, M. S., Bernstein, D. B., Glod, J. W., Kaplan, R. N., Grupp, S. A., Tap, W. D., Chagin, K., Binder, G. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1417 · Cited by 432 · see citing works

Distinctions Between CD8+ and CD4+ T-Cell Regenerative Pathways Result in Prolonged T-Cell Subset Imbalance After Intensive Chemotherapy

Mackall, C. L., Fleisher, T. A., Brown, M. R., Andrich, M. P., Chen, C. C., Feuerstein, I. M., Magrath, I. T., Wexler, L. H., Dimitrov, D. S., & Gress, R. E. (1997) · Blood · doi:10.1182/blood.v89.10.3700 · Cited by 400 · see citing works

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Blood · doi:10.1182/blood-2010-01-265041 · Cited by 392 · see citing works

Induction of various autoantibodies by mutant gene lpr in several strains of mice.

Izui, S., Kelley, V. E., Masuda, K., Yoshida, H., Roths, J. B., & Murphy, E. D. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.1.227 · Cited by 386 · see citing works

Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

Ramos, C. A., Ballard, B. C., Zhang, H., Dakhova, O., Gee, A. P., Mei, Z., Bilgi, M., Wu, M.-F., Liu, H., Grilley, B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94306 · Cited by 377 · see citing works

Prospects for gene-engineered T cell immunotherapy for solid cancers

Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 366 · see citing works

Landscape of immunogenic tumor antigens in successful immunotherapy of virally-induced epithelial cancer

Stevanović, S., Pasetto, A., Helman, S. R., Gartner, J. J., Prickett, T. D., Howie, B., Robins, H., Robbins, P., Klebanoff, C., Rosenberg, S., et al. (2017) · Science · doi:10.1126/science.aak9510 · Cited by 364 · see citing works

The role of CD95 and CD95 ligand in cancer

Peter, M. E., Hadji, A., Murmann, A. E., Brockway, S., Putzbach, W., Pattanayak, A., & Ceppi, P. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.3 · Cited by 356 · see citing works

Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma

Kleber, S., Sancho-Martinez, I., Wiestler, B., Beisel, A., Gieffers, C., Hill, O., Thiemann, M., Mueller, W., Sykora, J., Kuhn, A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.003 · Cited by 309 · see citing works

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study

Chandran, S. S., Somerville, R. P. T., Yang, J. C.-H., Sherry, R. M., Klebanoff, C. A., Goff, S. L., Wunderlich, J. R., Danforth, D. N., Zlott, D. A., Paria, B. C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30251-6 · Cited by 291 · see citing works

Abnormalities induced by the mutant gene Ipr: expansion of a unique lymphocyte subset.

Morse, H. C., Davidson, W. F., Yetter, R. A., Murphy, E. D., Roths, J. B., & Coffman, R. L. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.6.2612 · Cited by 291 · see citing works

Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

Klebanoff, C. A., Gattinoni, L., Palmer, D. C., Muranski, P. J., Ji, Y., Hinrichs, C. S., Borman, Z. A., Kerkar, S. P., Scott, C. D., Finkelstein, S. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0503 · Cited by 288 · see citing works

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3

Lu, Y., Parker, L. L., Lu, T., Zheng, Z., Toomey, M. A., White, D. E., Yao, X., Li, Y. F., Robbins, P. F., Feldman, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5463 · Cited by 278 · see citing works

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia

Paszkiewicz, P. J., Fräßle, S. P., Srivastava, S., Sommermeyer, D., Hudecek, M., Drexler, I., Sadelain, M., Liu, L., Jensen, M. C., Riddell, S. R., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84813 · Cited by 277 · see citing works

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Maus, M. V., & June, C. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1433 · Cited by 269 · see citing works

The Genotype-Tissue Expression (GTEx) project

Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., Hasz, R., Walters, G., Garcia, F., Young, N., et al. (2013) · Nature Genetics · doi:10.1038/ng.2653 · Cited by 263 · see citing works

Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy

Klebanoff, C. A., Scott, C. D., Leonardi, A. J., Yamamoto, T. N., Cruz, A. C., Ouyang, C., Ramaswamy, M., Roychoudhuri, R., Ji, Y., Eil, R. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81217 · Cited by 244 · see citing works

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes

Zhu, J., de Tenbossche, C. P., Canè, S., Colau, D., van Baren, N., Lurquin, C., Schmitt‐Verhulst, A., Liljeström, P., Uyttenhove, C., & den Eynde, B. J. V. (2017) · Nature Communications · doi:10.1038/s41467-017-00784-1 · Cited by 233 · see citing works

Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy

Klebanoff, C. A., Crompton, J. G., Leonardi, A. J., Yamamoto, T. N., Chandran, S. S., Eil, R. L., Sukumar, M., Vodnala, S. K., Hu, J., Ji, Y., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.95103 · Cited by 225 · see citing works

Autoimmune Lymphoproliferative Syndrome with Defective Fas: Genotype Influences Penetrance

Jackson, C. E., Fischer, R. E., Hsu, A. P., Anderson, S. M., Choi, Y., Wang, J., Dale, J. K., Fleisher, T. A., Middelton, L. A., Sneller, M. C., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302333 · Cited by 209 · see citing works

TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance

Yang, Y., Kohler, M. E., Chien, C. D., Sauter, C. T., Jacoby, E., Yan, C., Hu, Y., Wanhainen, K., Qin, H., & Fry, T. J. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1209 · Cited by 208 · see citing works

Engineering lymphocyte subsets: tools, trials and tribulations

June, C. H., Blazar, B. R., & Riley, J. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2635 · Cited by 199 · see citing works

How I treat autoimmune lymphoproliferative syndrome

Rao, V. K., & Oliveira, J. B. (2011) · Blood · doi:10.1182/blood-2011-07-325217 · Cited by 185 · see citing works

Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia

Martin, D. A., Zheng, L., Siegel, R. M., Huang, B., Fisher, G. H., Wang, J., Jackson, C. E., Puck, J. M., Dale, J. K., Straus, S. E., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4552 · Cited by 181 · see citing works

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma

Bollard, C. M., Tripic, T., Cruz, C. R., Dotti, G., Gottschalk, S., Torrano, V., Dakhova, O., Carrum, G., Ramos, C. A., Liu, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3179 · Cited by 181 · see citing works

Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity

Horton, B. L., Williams, J. B., Cabanov, A., Spranger, S., & Gajewski, T. F. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0249 · Cited by 167 · see citing works

4-1BB enhancement of CAR T function requires NF-κB and TRAFs

Li, G., Boucher, J. C., Kotani, H., Park, K., Zhang, Y., Shrestha, B., Wang, X., Guan, L., Beatty, N. J., Abate‐Daga, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121322 · Cited by 155 · see citing works

Apoptosis, fas and systemic autoimmunity: the MRL-Ipr/Ipr model

Singer, G. G., Carrera, A. C., Marshak‐Rothstein, A., Martínez‐A, C., & Abbas, A. K. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90013-2 · Cited by 152 · see citing works

Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry

Zheng, Z., Chinnasamy, N., & Morgan, R. A. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-29 · Cited by 146 · see citing works

T Cell–specific Ablation of Fas Leads to Fas Ligand–mediated Lymphocyte Depletion and Inflammatory Pulmonary Fibrosis

Hao, Z., Hampel, B., Yagita∥, H., & Rajewsky, K. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20032196 · Cited by 139 · see citing works

Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis

Dotti, G., Savoldo, B., Pulè, M. A., Straathof, K. C. M., Biagi, E., Yvon, E. S., Vigouroux, S., Brenner, M. K., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-08-3337 · Cited by 128 · see citing works

Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma

Veatch, J. R., Lee, S. M., Fitzgibbon, M., Chow, I., Jesernig, B. L., Schmitt, T., Kong, Y., Kargl, J., Houghton, A. M., Thompson, J. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98689 · Cited by 124 · see citing works

T-Cell Therapy Using Interleukin-21–Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression

Chapuis, A. G., Roberts, I. M., Thompson, J. A., Margolin, K. A., Bhatia, S., Lee, S. M., Sloan, H. L., Lai, I. P., Farrar, E. A., Wagener, F. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5142 · Cited by 122 · see citing works

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting

Slaney, C. Y., von Scheidt, B., Davenport, A. J., Beavis, P. A., Westwood, J. A., Mardiana, S., Tscharke, D. C., Ellis, S. L., Prince, H. M., Trapani, J. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1860 · Cited by 121 · see citing works

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD

Jacoby, E., Yang, Y., Qin, H., Chien, C. D., Kochenderfer, J. N., & Fry, T. J. (2015) · Blood · doi:10.1182/blood-2015-08-664250 · Cited by 114 · see citing works

Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies

Kerkar, S. P., Sanchez-Perez, L. A., Yang, S., Borman, Z. A., Muranski, P. J., Ji, Y., Chinnasamy, D., Kaiser, A., Hinrichs, C. S., Klebanoff, C. A., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182187600 · Cited by 99 · see citing works

Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy

Yi, F., Frazzette, N., Cruz, A. C., Klebanoff, C. A., & Siegel, R. M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.05.004 · Cited by 89 · see citing works

Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction

Cruz, A. C., Ramaswamy, M., Ouyang, C., Klebanoff, C. A., Sengupta, P., Yamamoto, T. N., Meylan, F., Thomas, S. K., Richoz, N., Eil, R. L., et al. (2016) · Nature Communications · doi:10.1038/ncomms13895 · Cited by 69 · see citing works

Specific elimination of effector memory CD4+ T cells due to enhanced Fas signaling complex formation and association with lipid raft microdomains

Ramaswamy, M., Cruz, A. C., Cleland, S. Y., Deng, M., Price, S. M., Rao, V. K., & Siegel, R. M. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.155 · Cited by 40 · see citing works

Protection from Autoimmune Diabetes and T-Cell Lymphoproliferation Induced by FasL Mutation Are Differentially Regulated and Can Be Uncoupled Pharmacologically

Mohamood, A. S., Guler, M. L., Xiao, Z., Zheng, D., Hess, A. D., Wang, Y., Yagita∥, H., Schneck, J. P., & Hamad, A. R. A. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070148 · Cited by 27 · see citing works

Defective clonal deletion and anergy induction in TCR transgenic lpr/lpr mice

Mountz, J. D., Bluethmann, H., Zhou, T., & Wu, J. (1994) · Seminars in Immunology · doi:10.1006/smim.1994.1005 · Cited by 26 · see citing works

Structural Requirements for Signal-induced Target Binding of FADD Determined by Functional Reconstitution of FADD Deficiency

Imtiyaz, H. Z., Zhang, Y., & Zhang, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504138200 · Cited by 24 · see citing works

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,477 · see citing works

Neoantigens: promising targets for cancer therapy

Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020 · see citing works

CAR immune cells: design principles, resistance and the next generation

Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 673 · see citing works

Navigating CAR-T cells through the solid-tumour microenvironment

Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 556 · see citing works

CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn

Albelda, S. Μ. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 535 · see citing works

The Emerging Landscape of Immune Cell Therapies

Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 445 · see citing works

CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?

Wagner, J., Wickman, E., DeRenzo, C. C., & Gottschalk, S. M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 383 · see citing works

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant

Yang, C. Q., Xia, B.-R., Zhang, Z.-C., Zhang, Y., Lou, G., & Jin, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577869 · Cited by 354 · see citing works

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 325 · see citing works

CAR T cells: Continuation in a revolution of immunotherapy

Singh, A. K., & McGuirk, J. P. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30823-x · Cited by 303 · see citing works

CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities

Fonkoua, L. A. K., Sirpilla, O. L., Sakemura, R. L., Siegler, E. L., & Kenderian, S. S. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.03.009 · Cited by 299 · see citing works

Promises and challenges of adoptive T-cell therapies for solid tumours

Morotti, M., Albukhari, A., Alsaadi, A., Artibani, M., Brenton, J. D., Curbishley, S. M., Dong, T., Dustin, M. L., Hu, Z., McGranahan, N., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01353-6 · Cited by 267 · see citing works

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

Dafni, U., Michielin, O. A., Lluesma, S. M., Tsourti, Z., Polydoropoulou, V., Karlis, D., Besser, M. J., Haanen, J. B. A. G., Svane, I. M., Ohashi, P. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz398 · Cited by 264 · see citing works

Challenges and new technologies in adoptive cell therapy

Zhang, P., Zhang, G., & Wan, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01492-8 · Cited by 271 · see citing works

Developing neoantigen-targeted T cell–based treatments for solid tumors

Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 237 · see citing works

Recent trends in cancer therapy: A review on the current state of gene delivery

Yahya, E. B., & Alqadhi, A. M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119087 · Cited by 240 · see citing works

Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts

Kerdidani, D., Aerakis, E., Verrou, K., Angelidis, I., Douka, K., Maniou, M.-A., Stamoulis, P., Goudevenou, K., Prados, A., Tzaferis, C., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210815 · Cited by 205 · see citing works

Targeting public neoantigens for cancer immunotherapy

Pearlman, A. H., Hwang, M. S., Konig, M. F., Hsiue, E. H.-C., Douglass, J., DiNapoli, S. R., Mog, B. J., Bettegowda, C., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00210-y · Cited by 192 · see citing works

Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies

Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.039 · Cited by 186 · see citing works

An engineered IL-2 partial agonist promotes CD8+ T cell stemness

Mo, F., Yu, Z., Li, P., Oh, J., Spolski, R. J., Zhao, L., Glassman, C. R., Yamamoto, T. N., Chen, Y., Gołębiowski, F., et al. (2021) · Nature · doi:10.1038/s41586-021-03861-0 · Cited by 183 · see citing works

Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies

Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 182 · see citing works

Gene modification strategies for next-generation CAR T cells against solid cancers

Tian, Y., Li, Y., Shao, Y., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00890-6 · Cited by 177 · see citing works

Genetic engineering of T cells for immunotherapy

Ellis, G. I., Sheppard, N. C., & Riley, J. L. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00329-9 · Cited by 166 · see citing works

T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome

Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A., & Ribas, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00809-z · Cited by 158 · see citing works

Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors

Fucà, G., Reppel, L., Landoni, E., Savoldo, B., & Dotti, G. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1835 · Cited by 147 · see citing works

Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors

Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133 · see citing works

Oncolytic virus-derived type I interferon restricts CAR T cell therapy

Evgin, L., Huff, A. L., Wongthida, P., Thompson, J., Kottke, T., Tonne, J., Schuelke, M., Ayasoufi, K., Driscoll, C. B., Shim, K. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17011-z · Cited by 128 · see citing works

Advancing CAR T cell therapy through the use of multidimensional omics data

Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 128 · see citing works

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment

Pearson, J. R. D., Cuzzubbo, S., McArthur, S., Durrant, L. G., Adhikaree, J., Tinsley, C. J., Pockley, A. G., & McArdle, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582106 · Cited by 118 · see citing works

Turning tumors from cold to inflamed to improve immunotherapy response

Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 113 · see citing works

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Zhang, Z., Wang, T., Wang, X.-F., Zhang, Y., Song, S., & Ma, C. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106036 · Cited by 103 · see citing works

Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy

Rath, J. A., & Arber, C. (2020) · Cells · doi:10.3390/cells9061485 · Cited by 99 · see citing works

Histone methyltransferase and drug resistance in cancers

Yang, C., Zhang, J., Ma, Y., Wu, C., Cui, W., & Wang, L. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01682-z · Cited by 86 · see citing works

CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity

Kong, Y., Li, J., Zhao, X., Wu, Y., & Chen, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1519671 · Cited by 91 · see citing works

Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies

Nolan-Stevaux, O., & Smith, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1490911 · Cited by 78 · see citing works

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 79 · see citing works

Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy

Lanitis, E., Irving, M. B., & Coukos, G. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01187-w · Cited by 73 · see citing works

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies

Springuel, L., Lonez, C., Alexandre, B., Cutsem, E. V., Machiels, J., den Eynde, M. V., Prenen, H., Hendlisz, A., Shaza, L., Carrasco, J., et al. (2019) · BioDrugs · doi:10.1007/s40259-019-00368-z · Cited by 68 · see citing works

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies

Huang, J., Huang, X., & Huang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019115 · Cited by 69 · see citing works

Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8 + T cells

Dwyer, C. J., Arhontoulis, D. C., Rivera, G. O. R., Knochelmann, H. M., Smith, A. S., Wyatt, M. M., Rubinstein, M. P., Atkinson, C., Thaxton, J. E., Neskey, D. M., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.201948455 · Cited by 64 · see citing works

Prospects and challenges for use of CAR T cell therapies in solid tumors

Ramakrishna, S., Barsan, V. V., & Mackall, C. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1738378 · Cited by 59 · see citing works

A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy

Oda, S. K., Anderson, K. G., Ravikumar, P., Bonson, P., Garcia, N. M., Jenkins, C. M., Zhuang, S., Daman, A. W., Chiu, E. Y., Bates, B. M., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191166 · Cited by 61 · see citing works

Antigen-specific depletion of CD4 + T cells by CAR T cells reveals distinct roles of higher- and lower-affinity TCRs during autoimmunity

Yi, J., Miller, A. T., Archambault, A. S., Jones, A., Bradstreet, T. R., Bandla, S., Hsu, Y.-S., Edelson, B. T., Zhou, Y. W., Fremont, D. H., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo0777 · Cited by 58 · see citing works

Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases

Risso, V., Lafont, É., & Gallo, M. L. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04688-x · Cited by 58 · see citing works

All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy

Lanitis, E., Coukos, G., & Irving, M. B. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.01.009 · Cited by 52 · see citing works

Activation-induced cell death in CAR-T cell therapy

Tian, H., Chen, D., Liu, G., Zhang, H., Wang, X., Wu, Z., Wu, Y. R., Xu, Q., & Yu, F. (2022) · Human Cell · doi:10.1007/s13577-022-00670-z · Cited by 50 · see citing works

An effective mouse model for adoptive cancer immunotherapy targeting neoantigens

Hanada, K., Yu, Z., Chappell, G. R., Park, A. S., & Restifo, N. P. (2019) · JCI Insight · doi:10.1172/jci.insight.124405 · Cited by 49 · see citing works

Tissue Site and the Cancer Immunity Cycle

Horton, B. L., Fessenden, T. B., & Spranger, S. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.006 · Cited by 50 · see citing works

CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit

Yi, F., Cohen, T., Zimmerman, N., Dündar, F., Zumbo, P., Eltilib, R., Brophy, E. J., Arkin, H., Feucht, J., Gormally, M. V., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01009-x · Cited by 52 · see citing works

Revving the CAR – Combination strategies to enhance CAR T cell effectiveness

Bansal, R., & Reshef, R. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100695 · Cited by 42 · see citing works

GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity

Cox, M. J., Roman, C. M., Tapper, E. E., Siegler, E. L., Chappell, D. B., Durrant, C., Ahmed, O., Sinha, S., Mwangi, R., Scott, N. E., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01572-7 · Cited by 41 · see citing works

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Petty, A. J., Heyman, B. M., & Yang, Y. (2020) · Cancers · doi:10.3390/cancers12040842 · Cited by 40 · see citing works

Understanding and improving cellular immunotherapies against cancer: From cell-manufacturing to tumor-immune models

Ringquist, R., Ghoshal, D., Jain, R., & Roy, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114003 · Cited by 39 · see citing works

Challenges and strategies associated with CAR-T cell therapy in blood malignancies

Liu, Z., Lei, W., Wang, H., Liu, X., & Fu, R. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00490-x · Cited by 43 · see citing works

Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade

Chi, A., He, X., Hou, L., Nguyen, N. P., Zhu, G., Cameron, R. B., & Lee, J. M. (2021) · Cancers · doi:10.3390/cancers13122924 · Cited by 35 · see citing works

Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy

Khatoon, E., Parama, D., Kumar, A., Alqahtani, M. S., Abbas, M. A. E., Girisa, S., Sethi, G., & Kunnumakkara, A. B. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120827 · Cited by 34 · see citing works

Central control of dynamic gene circuits governs T cell rest and activation

Arce, M. M., Umhoefer, J. M., Arang, N., Kasinathan, S., Freimer, J. W., Steinhart, Z., Shen, H., Pham, M. T. N., Ota, M., Wadhera, A., et al. (2024) · Nature · doi:10.1038/s41586-024-08314-y · Cited by 31 · see citing works

Mechanisms of response and resistance to CAR T cell therapies

Berger, T. R., & Maus, M. V. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.010 · Cited by 32 · see citing works

Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

Zhang, Y., Patel, R. P., Kim, K. H., Cho, H., Jo, J., Jeong, S. H., Oh, S. Y., Choi, Y. S., Kim, S. H., Lee, J. H., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01886-9 · Cited by 32 · see citing works

Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment

Bastien, J.-P., Minguy, A., Davé, V. P., & Roy, D. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101306 · Cited by 33 · see citing works

Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients

Saleki, K., Shirzad, M., Javanian, M., Mohammadkhani, S., Alijani, M. H., Miri, N., Oladnabi, M., & Azadmehr, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947401 · Cited by 32 · see citing works

Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics

Korell, F., Olson, M., Salas‐Benito, D., Leick, M. B., Larson, R. C., Bouffard, A. A., Silva, H. J., Gasparetto, A., Berger, T. R., Kann, M. C., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk7640 · Cited by 32 · see citing works

Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy

Drakes, D. J., Rafiq, S., Purdon, T. J., Lopez, A. V., Chandran, S. S., Klebanoff, C. A., & Brentjens, R. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0910 · Cited by 30 · see citing works

Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy

Wang, E., Cesano, A., Butterfield, L. H., & Marincola, F. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001619 · Cited by 30 · see citing works

Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells

Rad, S. M. A. H., Halpin, J. C., Mollaei, M., Smith‐Bell, S. W., Hirankarn, N., & McLellan, A. D. (2021) · Cancers · doi:10.3390/cancers13061229 · Cited by 31 · see citing works

Coengineering specificity, safety, and function into T cells for cancer immunotherapy

Attianese, G. M. P. G., Ash, S., & Irving, M. B. (2023) · Immunological Reviews · doi:10.1111/imr.13252 · Cited by 29 · see citing works

Integrated epigenetic and genetic programming of primary human T cells

Goudy, L., Ha, A. S., Borah, A. A., Umhoefer, J. M., Chow, L., Tran, C., Winters, A., Talbot, A., Hernandez, R., Li, Z., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02856-w · Cited by 32 · see citing works

Dendritic cell NLRC4 regulates influenza A virus–specific CD4+ T cell responses through FasL expression

Hornick, E. E., Dagvadorj, J., Zacharias, Z. R., Miller, A. M., Langlois, R. A., Chen, P., Legge, K. L., Bishop, G. A., Sutterwala, F. S., & Cassel, S. L. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124937 · Cited by 28 · see citing works

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy

Anderson, K. G., Oda, S. K., Bates, B. M., Burnett, M. G., Suarez, M. L. R., Ruskin, S. L., & Greenberg, P. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003959 · Cited by 28 · see citing works

Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death

Wang, Y., Zhang, H., Du, G., Luo, H., Su, J., Sun, Y., Zhou, M., Shi, B., Li, H. Q. X., Jiang, H., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.12.009 · Cited by 28 · see citing works

Ablation of FAS confers allogeneic CD3– CAR T cells with resistance to rejection by T cells and natural killer cells

Menegatti, S., López‐Cobo, S., Galy, A. S. D., Fuentealba, J. R., Silva, L. E., Perrin, L., Heurtebise-Chrétien, S., Pottez-Jouatte, V., Darbois, A., Burgdorf, N., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01282-8 · Cited by 28 · see citing works

miR-155 Overexpression in OT-1 CD8+ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen

Monnot, G., Martínez-Usatorre, A., Lanitis, E., Lopes, S. F., Cheng, W.-C., Ho, P., Irving, M. B., Coukos, G., Donda, A., & Romero, P. J. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.12.008 · Cited by 26 · see citing works

Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies

Dobrin, A., Lindenbergh, P. L., Shi, Y., Perica, K., Xie, H., Jain, N., Chow, A., Wolchok, J. D., Merghoub, T., Sadelain, M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00744-x · Cited by 23 · see citing works

Akt-Fas to Quell Aberrant T Cell Differentiation and Apoptosis in Covid-19

Leonardi, A. J., & Proenca, R. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600405 · Cited by 23 · see citing works

Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology

Choe, J. H., Williams, J. Z., & Lim, W. A. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033657 · Cited by 23 · see citing works

Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications for Adoptive T-Cell Therapy

Mika, T., Ladigan‐Badura, S., Maghnouj, A., Mustafa, B., Klein‐Scory, S., Baraniskin, A., Döhring, S., Fuchs, I., Ehl, S. R., Hahn, S. A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568056 · Cited by 22 · see citing works

Apoptosis: a Janus bifrons in T-cell immunotherapy

Lee, Y. G., Yang, N., Chun, I., Porazzi, P., Carturan, A., Paruzzo, L., Sauter, C. T., Guruprasad, P., Pajarillo, R., & Ruella, M. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005967 · Cited by 22 · see citing works

Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012–2023)

Miao, L., Zhang, J., Xu, W., Qian, Q., Zhang, G., Yuan, Q., Lv, Y., Zhang, H., Shen, C., & Wang, W. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2338984 · Cited by 22 · see citing works

The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies

Zhylko, A., Winiarska, M., & Graczyk‐Jarzynka, A. (2020) · Cancers · doi:10.3390/cancers12082030 · Cited by 21 · see citing works

Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies

Anderson, K. G., Braun, D. A., Buqué, A., Gitto, S. B., Guerriero, J. L., Horton, B. L., Keenan, B. P., Kim, T. S., Overacre-Delgoffe, A. E., Ruella, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006533 · Cited by 21 · see citing works

Clinical Investigations of CAR-T Cell Therapy for Solid Tumors

Chen, K., Wang, S., Qi, D., Ma, P., Fang, Y., Jiang, N., Wu, E., & Li, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896685 · Cited by 20 · see citing works

Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours

Mao, R., Hussein, M. S., & He, Y. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.32 · Cited by 20 · see citing works

Synergistic combination of oncolytic virotherapy with CAR T-cell therapy

Ajina, A., & Maher, J. F. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.015 · Cited by 20 · see citing works

Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job

Schwerdtfeger, M., Benmebarek, M.-R., Endres, S., Subklewe, M. S., Desiderio, V., & Kobold, S. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00628-2 · Cited by 18 · see citing works

A synthetic biology approach to engineering circuits in immune cells

Hoces, D., Blanco, J. M., & Hernández-López, R. A. (2023) · Immunological Reviews · doi:10.1111/imr.13244 · Cited by 18 · see citing works

New targets and technologies for CAR-T cells

Freitag, F., Maucher, M., Riester, Z., & Hudecek, M. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000653 · Cited by 18 · see citing works

CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence

Richards, D. M., Merz, C., Gieffers, C., & Krendyukov, A. (2021) · Cancer Management and Research · doi:10.2147/cmar.s297499 · Cited by 16 · see citing works

Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain

Mikkilineni, L., Natrakul, D. A., Lam, N., Manasanch, E. E., Mann, J., Weissler, K. A., Wong, N., Brudno, J. N., Goff, S. L., Yang, J. C., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.12.018 · Cited by 16 · see citing works

QBEmax is a sequence-permuted and internally protected base editor

Hu, J., Guo, M., Gao, Q., Jia, H., He, M., Wang, Z., Guo, L., Liu, G., Gao, Q., & Zhao, K. T. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02641-9 · Cited by 16 · see citing works

Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand–Expressing Solid Tumors

Bajgain, P., Chavez, A. G. T., Balasubramanian, K., Fleckenstein, L., Lulla, P., Heslop, H. E., Vera, J. F., & Leen, A. M. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0115 · Cited by 15 · see citing works

Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy

McKenzie, C., El-Kholy, M., Parekh, F., Robson, M., Lamb, K., Allen, C., Sillibourne, J., Cordoba, S.-P., Thomas, S., & Pule, M. (2023) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2023.04.017 · Cited by 11 · see citing works

Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors

Spiga, M., Martini, E., Maffia, M. C., Ciceri, F., Ruggiero, E., Potenza, A., & Bonini, C. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01011-y · Cited by 15 · see citing works

Unlocking Apoptotic Pathways: Overcoming Tumor Resistance in CAR ‐T‐Cell Therapy

Zhang, Z., Su, M., Jiang, P., Wang, X., Tong, X., & Wu, G. (2024) · Cancer Medicine · doi:10.1002/cam4.70283 · Cited by 17 · see citing works

CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer

Li, M., Li, S., Zhao, R., Lv, J., Zheng, D., Qin, L., Li, S., Wu, Q., Long, Y., Tang, Z., et al. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00967-1 · Cited by 13 · see citing works

Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors

James, S. E., Chen, S., Ng, B. D., Fischman, J. S., Jahn, L., Boardman, A. P., Rajagopalan, A., Elias, H. K., Massa, A., Manuele, D., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01287-3 · Cited by 13 · see citing works

Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments

Soler, D. C., Kerstetter-Fogle, A. E., McCormick, T. S., & Sloan, A. E. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03902-8 · Cited by 13 · see citing works

Intelligent cell-based therapies for cancer and autoimmune disorders

Chen, R., Ji, J., Siwko, S. K., Huang, Y., & Zhou, Y. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.08.012 · Cited by 12 · see citing works

Synthetic Biology and Biomaterials Strategies to Deceive the Tumor Microenvironment in CAR‐T Immunotherapy

Marsico, G., Sudarshan, G. C., & Siciliano, V. (2025) · Small · doi:10.1002/smll.202506429 · Cited by 11 · see citing works

Mechanisms of Resistance to CAR T-Cells and How to Overcome Them

Legato, L., Bisio, M., Fasano, F., Savelli, C. B., Secreto, C., Dellacasa, C., Botto, B., Busca, A., Cerrano, M., Freilone, R., et al. (2025) · Methods and Protocols · doi:10.3390/mps8050108 · Cited by 13 · see citing works

Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy

Bridge, J. E., Johnson, M. J., Kar, B., Kim, J., Wenthe, S. J., Krueger, J. B., Wick, B. J., Kluesner, M. G., Crane, A. T., Bell, J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.007 · Cited by 11 · see citing works

Abstract PR05: T-cells engineered to overcome death signaling within the tumor microenvironment enhance adoptive cancer immunotherapy

Klebanoff, C. A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6074.cricimteatiaacr18-pr05

Engineering Cd8+ T Cells To Overcome Death Signaling Within The Tumor Microenvironment

Yamamoto, T. N. (2019) · ScholarlyCommons (University of Pennsylvania)

Engineered T Cells Bypass Death Signaling and Bolster Immunotherapy

(2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2019-033

Abstract 40: Persistence but not antitumor efficacy of CAR-engineered lymphocytes is governed by a FAS/FAS ligand auto-regulatory circuit

Yi, F., Cohen, T., Zumbo, P., Eltilib, R., Arkin, H., Gormally, M. V., Hackett, C. S., Kropp, K. N., Chandran, S. S., Park, J. H., et al. (2024) · Cancer Research · doi:10.1158/1538-7445.am2024-40 · Cited by 1 · see citing works

175 A Fas-4–1BB immunomodulatory fusion protein converts a pro-death to a pro-survival signal, enhancing T cell function and efficacy of adoptive cell therapy in murine models of AML and pancreatic cancer

Oda, S. K., Anderson, K. G., Greenberg, P. D., Garcia, N. M., Ravikumar, P., Bonson, P., Jenkins, C. M., Zhuang, S., Daman, A. W., & Shannon (2020) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2020-sitc2020.0175 · Cited by 1 · see citing works